Loosening, Prosthesis Clinical Trial
Official title:
Application of Advanced High-sensitivity Technologies for Identifying Infections in Patients With Aseptic Loosening of Hip Arthroplasty.
Verified date | March 2024 |
Source | Istituto Ortopedico Rizzoli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Recent data showed that the rate of periprosthetic infections in patients undergoing a hip arthroplasty revision for aseptic loosening is higher than what can be ascertained with conventional methods. The study aims to assess the adequacy of next-generation sequencing of 16s ribosomal ribonucleic acid (rRNA) gene amplicons for identifying occult infections and improving the diagnostic workup. Moreover, additional testing has been planned in order to increase knowledge on the etiopathogenesis of infection.
Status | Completed |
Enrollment | 11 |
Est. completion date | February 15, 2024 |
Est. primary completion date | December 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Hip arthroplasty revision for aseptic loosening, diagnosis determined as probable according to the following criteria: - pain and/or functional impairment; - radiographic signs of osteolysis following wear of the implant components, or cortical reaction, or periprosthetic bone resorption; - negative evaluation by the infectious disease specialist. Exclusion Criteria: - presence of a sinus tract communicating with the arthroplasty; - bacteria isolation from aspirates or blood cultures performed preoperatively; - serum C-reactive protein higher than 10 mg/L; - recurrent implant dislocations; - prosthetic fracture; - medical history for septic arthritis, osteomyelitis; - infections in anatomic areas other than hip; - antibiotic therapy in the 15 days prior to surgery (with the exception of preoperative antibiotic prophylaxis); - chronic treatment with immunosuppressive drugs; - medical contraindications for executing sample collection. |
Country | Name | City | State |
---|---|---|---|
Italy | Istituto Ortopedico Rizzoli | Bologna |
Lead Sponsor | Collaborator |
---|---|
Istituto Ortopedico Rizzoli |
Italy,
Goswami K, Parvizi J. Culture-negative periprosthetic joint infection: is there a diagnostic role for next-generation sequencing? Expert Rev Mol Diagn. 2020 Mar;20(3):269-272. doi: 10.1080/14737159.2020.1707080. Epub 2019 Dec 24. No abstract available. — View Citation
Pajarinen J, Jamsen E, Konttinen YT, Goodman SB. Innate immune reactions in septic and aseptic osteolysis around hip implants. J Long Term Eff Med Implants. 2014;24(4):283-96. doi: 10.1615/jlongtermeffmedimplants.2014010564. — View Citation
Tarabichi M, Shohat N, Goswami K, Alvand A, Silibovsky R, Belden K, Parvizi J. Diagnosis of Periprosthetic Joint Infection: The Potential of Next-Generation Sequencing. J Bone Joint Surg Am. 2018 Jan 17;100(2):147-154. doi: 10.2106/JBJS.17.00434. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of microorganisms by microbiological cultures (number of patients with positive microbiological culture). | Tissue samples will be sent for microbiological cultures and treated for the isolation of aerobic and anaerobic pathogens. The existence of two positive cultures will be considered to be diagnostic for periprosthetic infection; a single positive culture may occur from a contaminating organism and will be considered in conjunction with other markers of infection, including histological features. | Within two week of admission | |
Primary | Number of patients with histological features of periprosthetic infection | The presence of a periprosthetic infection will be established according to the number of polymorphonuclear cells (PMN) counted in ten high-power fields (HPF) (400 × magnification, field diameter 0.54 mm)- Uninfected: 0-5 PMNs in 10 HPFs; borderline, but probably not infected: 6-10 PMNs for 10 HPF; borderline, but probably infected: >10 PMNs for 10 HPFs (but not > 5 PMNs in a single HPF); infected > 5 for HPF. | Within two week of admission | |
Primary | Identification of microorganisms by next-generation sequencing (NGS) (number of patients with positive NGS). | The NGS will be employed to characterize the overall microbiome profile in tissue samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation, alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances), and beta-diversity (differences in microbial community composition between samples). | Through study completion, an average of 6 months. | |
Secondary | Characterization of taxonomic and phylogenetic affiliation of gut microbiota | The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation. | Through study completion, an average of 6 months. | |
Secondary | Characterization of alpha-diversity and beta-diversity of gut microbiota | The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples). | Through study completion, an average of 6 months. | |
Secondary | Characterization of taxonomic and phylogenetic affiliation of oral microbiota | The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine the taxonomic and phylogenetic affiliation. | Through study completion, an average of 6 months. | |
Secondary | Characterization of alpha-diversity and beta-diversity of oral microbiota | The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples | Through study completion, an average of 6 months. | |
Secondary | Number of patients with inflammatory cellular reactivity related to bacterial products. | The inflammatory cellular reactivity proved by the presence of activated macrophages and Toll-like-receptor positive cells. | Through study completion, an average of 6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05508958 -
Cup Revisions Through Anterior or Posterolateral Approach: an RCT
|
N/A | |
Recruiting |
NCT05204797 -
Efficacy of Robot-assisted Technique vs Conventional Technique in Preventing Early Micromobilisation After UKA
|
N/A |